Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › enasidenib

enasidenib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of enasidenib

3 trials tracked of enasidenib.

3Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 3
  1. Phase 2 Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Completed
  2. Phase 2 Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed
  3. Phase 2 Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Metabolic reprogramming and plasticity drive tumor progression and resistance through interconnected transcription factors and enzymes
Oncology Sys. Review
Metabolic reprogramming and plasticity drive tumor progression and resistance through interconnected transcription factors and enzymes Metabolic Plasticity Drives Cancer Growth and Resistance
This narrative review examines how metabolic reprogramming, driven by transcription factors like MYC and HIF-1α, facilitates cancer progress…
Cancer cells rewire their metabolism to fuel growth and resist treatment. A new review maps the complex network behind this process.
Frontiers Jul 29, 2026